Obesity is a chronic condition characterized by excess adipose tissue, whose clinical significance depends on its distribution, function, and effects on organs. In cardiovascular medicine, it increases the likelihood of atherosclerosis, heart failure, atrial fibrillation, and other complications through metabolic, hemodynamic, and inflammatory mechanisms. Its relationship with clinical events cannot be fully described by body weight and is not limited to the higher prevalence of diabetes and hypertension.
BMI, calculated by dividing weight in kilograms by the square of height in meters, remains useful for screening and classification. However, it does not distinguish fat from muscle, identify fat deposits, and may be affected by fluid retention. Cardiovascular assessment should therefore also consider abdominal anthropometry, exposure history, functional capacity, associated risk factors, and evidence of existing organ damage.
The increasing prevalence of obesity and its progressively earlier onset extend the duration of cumulative exposure. Individual risk remains heterogeneous: visceral adiposity, diabetes, kidney function, smoking, blood pressure, and fitness can produce important differences at the same BMI. Recognizing this variability allows personalized care, without automatically considering excess adiposity harmless simply because no overt complications are present at a given time.
Positive energy balance is necessary for tissue mass accumulation, but it does not fully explain the etiology. Polygenic susceptibility, appetite regulation, food availability, sleep, medications, the built environment, and opportunities for physical activity affect intake and expenditure. Weight gain cannot reliably be explained by individual willpower alone. Endocrine disorders and rare monogenic forms account for a minority of cases and should be investigated when specific clues are present.
Central regulation integrates signals such as leptin, insulin, and gastrointestinal hormones with hypothalamic circuits and reward systems. After weight loss, hunger and metabolic adaptation may increase, favoring weight regain. This biological response contributes to the chronic nature of obesity and explains why a strategy effective for several months may require continued support. Failure to maintain weight loss does not prove that the initial treatment was useless, but calls for reassessment of its intensity and sustainability.
When adipocytes expand beyond the functional capacity of adipose tissue, cellular stress, extracellular matrix remodeling, and immune activation increase. Adipose tissue dysfunction changes adipokine secretion and fatty acid availability. Lipids may accumulate in the liver, skeletal muscle, and myocardium, where bioactive intermediates interfere with insulin signaling, metabolism, and cellular function. The quantity of fat and the characteristics of its storage sites thus become complementary dimensions.
Visceral fat is associated with an unfavorable metabolic profile, whereas some peripheral subcutaneous depots may act as relatively less harmful storage compartments. Epicardial adipose tissue, which lies adjacent to the heart without complete fascial separation from the myocardium, may locally influence inflammation and atrial tissue. However, associations with risk and function do not justify using a single epicardial fat measurement as a universal diagnostic test or an independent treatment target.
The atherosclerotic pathway involves increased apoB-containing particles, insulin resistance, endothelial changes, and inflammation. LDL-C may appear only moderately elevated while non-HDL cholesterol and apoB reveal a greater atherogenic burden. Concurrent smoking, hypertension, and diabetes increase opportunities for vascular injury. Reducing adipose mass improves several determinants but does not automatically replace lipid-lowering therapy warranted by established disease or risk.
Greater tissue mass requires increased perfusion and is associated with expansion of blood volume and increased cardiac output. Sodium retention and activation of sympathetic and renin-angiotensin-aldosterone systems may promote hypertension. The left ventricle responds to varying volume and pressure loads through remodeling and hypertrophy; stiffness and filling pressures increase over time, especially when nephropathy and sleep-related breathing disorders coexist.
Obesity-associated heart failure with preserved ejection fraction involves a combination of systemic inflammation, microvascular dysfunction, metabolic abnormalities, volume expansion, and mechanical constraints. Fat accumulation and its interaction with the pericardium may accentuate the volume dependence of intracardiac pressures. Dyspnea may become apparent mainly during exertion, when filling pressures rise despite an apparently normal ejection fraction.
Obesity may also contribute to heart failure with reduced ejection fraction, either directly or through coronary artery disease and hypertension. However, systolic dysfunction in a person with obesity must not automatically be attributed to weight: ischemia, valvular disease, toxic exposures, myocarditis, and genetic cardiomyopathies remain possible diagnoses. The term obesity-associated cardiomyopathy requires evaluation of the clinical context and competing causes.
Atrial remodeling includes dilatation, increased pressure, fatty infiltration, and fibrosis, promoting atrial fibrillation. Sleep apnea and hypertension amplify the substrate through intermittent hypoxia and autonomic activation. The risk of arrhythmia and recurrence therefore reflects several modifiable processes; weight management is integrated with arrhythmia treatment and thromboembolic prevention when indicated.
Obstructive sleep apnea and, where applicable, obesity hypoventilation syndrome may increase right ventricular load, hypoxemia, and pulmonary pressure. Obesity also promotes venous stasis and prothrombotic conditions, contributing to thromboembolic risk, especially during immobilization or surgery. These mechanisms differ from arterial plaque disease and require their own prevention and diagnostic approaches.
Kidney disease may involve early hyperfiltration, glomerular changes, elevated blood pressure, and subsequent functional decline. Impaired kidneys in turn aggravate fluid retention, vascular risk, and treatment tolerability. Cardiorenal assessment is therefore part of characterizing clinically significant obesity, rather than an investigation reserved for people who already have diabetes.
Obesity may be recognized before any complication or during investigation of dyspnea, chest pain, or arrhythmia. Reduced exercise tolerance may result from deconditioning and the energy cost of movement, but also from heart failure, ischemia, respiratory disease, or anemia. Attributing symptoms solely to weight risks delaying a treatable diagnosis. The history must distinguish stable limitations from recent deterioration.
History-taking reconstructs age at onset and duration, maximum weight, intentional or spontaneous changes, previous treatments, and reasons for discontinuation. Rapid weight gain with edema suggests fluid accumulation; unintentional weight loss may indicate systemic disease or advanced heart failure. Family history, eating behavior, sleep disturbances, medications, and socioeconomic and environmental circumstances help clarify the realistic options for intervention.
Orthopnea, paroxysmal nocturnal dyspnea, reduced walking capacity, and increasing edema suggest congestion. Palpitations and an irregular pulse suggest arrhythmia; snoring and daytime sleepiness point to sleep-related breathing disorders. Exertional chest pain, claudication, and transient neurological deficits require vascular assessment appropriate to the affected territory. None of these findings is adequately explained by BMI alone.
Accurate blood pressure measurement requires a validated cuff of appropriate size and shape for the arm, whose configuration may make measurement difficult. A cuff that is too small may overestimate the reading. Examination includes heart rate and rhythm, jugular venous distension when assessable, auscultation, pulses, and edema; technical difficulty does not justify omitting examination. Skin findings and adipose distribution may suggest endocrine conditions or rare metabolic disorders.
Assessment of physical function includes strength, balance, independence, and ability to be active. Sarcopenic obesity combines excess adiposity with reduced muscle mass or function and may not be obvious from body weight. In older people or those with heart failure, a program based solely on rapid weight loss may worsen frailty and disability. Functional and nutritional goals should be defined before treatment.
The presence of eating disorders, depression, stigma, or repeated negative treatment experiences affects the care pathway. Psychological assessment is not intended to demonstrate that obesity is a “psychological” disease, but to identify needs that influence treatment safety and continuity. Clinical language should describe the person and their condition without judgments about character.
Under conventional adult classification, a BMI of 25–29.9 kg/m² denotes overweight and a BMI of at least 30 denotes obesity, with class I at 30–34.9, class II at 35–39.9, and class III at 40 or above. Some populations, particularly Asian populations, develop complications at lower levels and require adapted cutoffs. These ranges describe anthropometric categories; they do not independently demonstrate cardiovascular damage or measure the distribution of fat depots.
Waist circumference and the waist-to-height ratio complement screening for central adiposity. A ratio above 0.5 is a useful marker in several assessment frameworks and should be interpreted in context. When BMI, appearance, and function are discordant, body composition techniques such as DXA or bioelectrical impedance can add information; hydration, edema, and methodological limitations affect interpretation.
The 2024 EASO framework proposes combining anthropometric criteria with the presence and severity of medical, functional, and psychological complications. It also considers people with BMI of at least 25, central adiposity, and clinical impairment, moving beyond a classification based solely on the BMI threshold of 30. Its aim is to better describe adiposity-based disease and guide management, not to make every increase in waist circumference equivalent to a cardiovascular complication.
The 2025 Lancet Commission distinguishes clinical and preclinical obesity: in the former, excess adiposity is accompanied by organ dysfunction or significant limitations in daily activities; in the latter, function is preserved but future risk remains. It recommends confirming excess adiposity beyond BMI alone, except when it is evident. This is an authoritative proposal for definition and staging and should be recognized as such: the different diagnostic frameworks have not yet become one classification applied identically in every healthcare system.
The practical distinction is between quantity, distribution, and consequences. A cardiovascular diagnosis requires documentation of the relevant disease, while confirmation of excess adiposity guides prevention and treatment even before an event occurs. Someone without measurable complications should not be reassured as though lifetime risk were zero; equally, risk must not be converted into a diagnosis of heart disease that has not been demonstrated.
Differential diagnosis includes fluid retention, high muscle mass, lipodystrophies, and endocrine disorders. Hypothyroidism or hypercortisolism is investigated when consistent findings are present, while very early-onset obesity with marked hyperphagia and syndromic features may warrant genetic consultation. Indiscriminate hormonal or genetic panels are not required in routine assessment.
Initial tests characterize glycemia, lipids, and kidney function: fasting glucose or HbA1c, a complete lipid profile, creatinine with eGFR, and albuminuria when appropriate. ApoB and non-HDL cholesterol can clarify a discordant lipid profile. Liver enzymes and, where indicated, pathways to assess fibrosis complete the metabolic assessment; they do not directly diagnose coronary risk. Lp(a) measurement in adults identifies an inherited component independent of adiposity.
Suspected heart failure calls for ECG, natriuretic peptides, and echocardiography according to the clinical presentation. In obesity, BNP and NT-proBNP may be lower than in people with comparable cardiac impairment but different body composition: a modest elevation does not automatically exclude HFpEF. A poor acoustic window may require additional techniques, while interpretation of cardiac chamber dimensions must account for the limitations of indexing to body surface area.
Echocardiography assesses structure, systolic and diastolic function, valves, the right ventricle, and estimated pressures. Normal ejection fraction does not end the investigation if compatible symptoms persist. When resting tests are inconclusive, exercise testing with functional or hemodynamic assessment may clarify mechanisms of dyspnea in experienced centers. One isolated abnormality is insufficient to attribute all symptoms to HFpEF.
Assessment for coronary ischemia follows clinical probability, symptoms, and indications. Severe obesity, calcification, exercise capacity, and technical factors may affect the quality of stress echocardiography, nuclear imaging, CT, or MRI. The patient's weight and dimensions must be compatible with equipment, without abandoning the diagnostic question. Asymptomatic obesity alone is not an indication for invasive coronary angiography or repeated ischemia screening.
If palpitations or an irregular pulse are present, documenting heart rhythm requires an ECG and, when useful, prolonged monitoring. A diagnosis of atrial fibrillation leads to assessment of symptoms, embolic risk, cardiac function, and factors supporting recurrence. Weight loss does not replace an indication for anticoagulation; drug choice and dose must take account of kidney function, extreme body weight, and previous bariatric surgery when relevant.
Suspected obstructive sleep apnea requires a dedicated respiratory assessment; hypoventilation is not diagnosed from sleepiness alone. Dyspnea and edema may have several causes at once. Thromboembolic risk assessment is particularly relevant during immobilization, hospitalization, and surgical planning, but does not entail permanent anticoagulant prophylaxis for everyone with obesity.
Prognostic risk stratification integrates existing disease and conventional risk factors. BMI should not be arbitrarily added to a model as though it produced a fixed risk percentage. In selected patients, coronary artery calcium scoring can help resolve an uncertain preventive decision; in those with established atherosclerosis, appropriate treatment is the priority, without waiting for further proof of risk.
The treatment plan defines clinical goals beyond weight: improved blood pressure and metabolism, symptom reduction, greater independence, and prevention of clinical events. Initial weight loss of 5–10% may produce metabolic benefits, while certain complications require larger, sustained reductions. Targets are agreed according to severity, age, and available treatment; reaching a normal BMI is not necessary before a meaningful improvement can be recognized.
Nutritional therapy establishes a sustainable energy deficit when indicated, while maintaining adequate protein, fiber, micronutrients, and dietary fat quality. There is no single ideal macronutrient distribution for everyone. Heart disease, nephropathy, diabetes, and medications influence the choice: a rapid reduction in food intake may require adjustments in insulin or diuretics. Extreme restrictions, dehydration, and muscle loss are not desirable outcomes.
Aerobic and resistance exercise supports cardiorespiratory fitness and muscle preservation. Progression must take account of ischemia, heart failure, musculoskeletal limitations, and fall risk. Physical activity can improve health and function even without large weight changes, while resistance training is particularly useful during substantial weight loss. Supervised programs and cardiac rehabilitation may make exercise feasible in more complex patients.
Behavioral therapy includes tracking habits, organizing meals, identifying triggers for relapse, and supporting continuity. Weight regain is analyzed without blame, considering hunger, biological adaptation, treatment access, and life changes. Addressing sleep and medications that favor weight gain may improve response when clinically appropriate alternatives exist.
The Look AHEAD trial assessed an intensive lifestyle intervention in adults with type 2 diabetes and overweight or obesity. Although the program improved weight, physical fitness, and several metabolic factors, it did not significantly reduce the composite cardiovascular outcome compared with the control group. This finding does not negate the intervention's functional and metabolic benefits but prevents inferring event prevention from weight loss alone. It is also not directly comparable with a drug trial conducted in people without diabetes who already have documented atherosclerosis.
Anti-obesity medications are used as part of long-term management in patients who meet the individual drug's indications. Many authorizations use BMI of at least 30, or at least 27 with related complications, but eligibility, availability, and reimbursement are not identical across settings. Choice takes account of cardiovascular disease, diabetes, adverse effects, interactions, pregnancy plans, and the feasibility of continued treatment. Administrative cutoffs do not exhaust clinical assessment.
The GLP-1 receptor agonist semaglutide, in the subcutaneous 2.4 mg weekly regimen studied in STEP 1, produced substantial mean weight loss in adults without diabetes, together with metabolic improvements. Gradual dose titration improves gastrointestinal tolerability. Results from a weight-loss trial do not automatically establish an effect on myocardial infarction or mortality: these outcomes were evaluated separately.
In SELECT, 17,604 people with established cardiovascular disease, BMI of at least 27, and no diabetes were assigned to semaglutide 2.4 mg or placebo in addition to usual care. The composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke occurred in 6.5% versus 8.0%, with a hazard ratio of 0.80. The result supports cardiovascular protection in the population studied; it does not establish the same benefit in every young person with obesity but no disease, nor quantify how much of the benefit is attributable exclusively to kilograms lost.
Tirzepatide, a dual GIP and GLP-1 receptor agonist, demonstrated dose-dependent mean weight reductions in SURMOUNT-1, reaching approximately 21% at 72 weeks with the 15 mg dose, versus approximately 3% with placebo. Participants did not have diabetes, and the mean results do not guarantee an individual response. Other clinical programs address specific complications and must be interpreted according to their respective designs.
In the SUMMIT trial, tirzepatide was studied in people with obesity and HFpEF. It reduced the composite of cardiovascular death or worsening heart failure and improved health status; the advantage in the composite was primarily driven by fewer worsening heart failure episodes. The small number of cardiovascular deaths does not justify describing a separately demonstrated mortality benefit. Adiposity treatment is therefore combined with heart failure therapy and congestion management.
Adverse effects of incretin-based therapies mainly include nausea, vomiting, diarrhea, or constipation, with possible dehydration when symptoms are severe. Biliary disease, symptoms suggestive of pancreatitis, gastroparesis, and other medical history factors require attention according to the medication. Hypoglycemia mainly concerns combination with insulin or secretagogues, whose doses may need reduction. Weight loss should be accompanied by monitoring of protein intake and muscle function; pregnancy or pregnancy planning requires discontinuation or management according to specific guidance.
Other drug options have different mechanisms and limitations. Orlistat reduces fat absorption and may cause gastrointestinal effects and nutritional interference; naltrexone/bupropion requires particular attention to blood pressure, heart rate, contraindications, and interactions. Not all weight-loss treatments have demonstrated cardiovascular protection. In known heart disease, hemodynamic safety and clinical event evidence must influence the choice, alongside the magnitude of weight loss.
Metabolic surgery produces substantial weight loss and may improve diabetes and other risk factors. The 2022 ASMBS/IFSO recommendations advise consideration of surgery at BMI of at least 35 regardless of comorbidity severity and also consider treatment between 30 and 34.9 in the presence of metabolic disease or an inadequate response to nonsurgical approaches. Local operational criteria may differ. Decisions require a multidisciplinary team, nutritional and psychological assessment, evaluation of cardiopulmonary risk, and informed agreement about benefits and lifelong commitments.
Associations between surgery and reduced clinical events or mortality are largely supported by observational studies and prospective cohorts; randomized trials have mainly documented weight and metabolic outcomes. This distinction does not eliminate potential benefits but defines the quality of the evidence. Procedure selection depends on surgical technique, reflux, diabetes, comorbidities, and nutritional risk. Follow-up, supplementation, and deficiency monitoring must continue even after weight stabilizes.
Treatment of coexisting cardiovascular conditions proceeds in parallel. Statins, antihypertensives, heart failure medications, and thromboembolic prevention retain their own indications. After substantial weight loss, reducing doses of diuretics, antihypertensives, or glucose-lowering therapies may be necessary to prevent excessive effects, while a previous myocardial infarction remains relevant even after BMI decreases. Dose review must follow clinical and functional measurements.
In patients with heart failure and frailty, volume status must be distinguished from body composition. Rapid weight reduction after diuretic treatment mainly represents decongestion; unintentional weight loss accompanied by muscle loss may indicate deterioration. Calorie restriction should not be mechanically applied to those with malnutrition or cachexia. In type 1 diabetes, older age, and advanced kidney disease, additional adjustments are necessary.
Monitoring includes weight and waist circumference, blood pressure, heart rate, symptoms, blood glucose, kidney function, tolerability, and muscle function according to treatment. An inadequate response prompts review of adherence, dosage, aggravating causes, and strategy suitability. Stopping an effective medication may promote weight regain; long-term maintenance should be planned from the outset, rather than describing a chronic disease as cured by a short treatment course.
Cardiovascular prognosis reflects the duration and phenotype of excess adiposity, existing disease, and control of risk factors. Apparently “metabolically healthy” obesity may progress over time and does not guarantee the absence of risk. Cardiorespiratory fitness and muscle preservation improve interpretation but do not make persistent, substantial visceral adiposity irrelevant.
The so-called obesity paradox, observed in some cohorts of people with established heart disease, describes associations between higher BMI and better survival in certain settings. Patient selection, smoking, disease-related weight loss, body composition, and fitness may contribute. These findings do not establish that gaining fat is protective or that appropriate, monitored intentional weight loss is harmful. Intervention studies address a different question from observational associations.
Complications include atherothrombosis, heart failure, and arrhythmias, along with venous thromboembolism, nephropathy, and respiratory disorders that may worsen cardiac function. Damage is often multidimensional: a person may improve blood glucose but remain symptomatic because of heart failure, or lose weight without achieving adequate lipid control. Assessment of outcomes must therefore keep these different domains separate.
Treatment complications include muscle loss and deficiencies, as well as drug- and surgery-specific adverse effects. They can be prevented or detected early through appropriate selection, nutrition, and monitoring. The best clinical outcome is sustained risk reduction accompanied by better function and independence, not the lowest body weight achievable at any cost.
Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.
Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.